Etanercept in Hidradenitis Suppurativa

Mise à jour : Il y a 4 ans
Référence : NCT00329823

Femme et Homme

  • | Pays :
  • Greece
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The rationale of the protocol is based on the reported beneficiary results of case-patients by the administration of other anti-TNF drug (infliximab) in separate cases on the grounds of a probable autoimmune predisposition of the disease. The objective of this study is to clarify the potency of etanercept for the therapy of hidradenitis suppurativa.


Critère d'inclusion

  • Hidradenitis Suppurativa

Liens